Central nervous system lupus

Summary

Central nervous system lupus (MONDO:0043985) is a disease and 4 clinical trials. Top therapeutic interventions include tocilizumab. A subtype of autoimmune disorder of central nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central nervous system lupus
Mondo ID	MONDO:0043985
MeSH	D020945
NCIT	C116919
UMLS	C0752332
MedGen	156265
GARD	0025875
Is cancer (heuristic)	no

Also known as: central nervous system lupus · central nervous system lupus vasculitis · central nervous system systemic lupus Erythematosis · CNS lupus · lupus Meningoencephalitides · lupus meningoencephalitis · Meningoencephalitides, lupus · meningoencephalitis, lupus · neuropsychiatric systemic lupus erythematosus · systemic lupus Erythematosis, central nervous system

Disease family

This is a subtype of autoimmune disorder of central nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › central nervous system lupus

Related subtypes (7): multiple sclerosis, Miller Fisher syndrome, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, lymphocytic hypophysitis, autoimmune encephalitis, autoimmune optic neuritis, autoimmune epilepsy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07281105	PHASE2	COMPLETED	EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
NCT05017142	Not specified	RECRUITING	Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT05934149	Not specified	RECRUITING	Lupus Landmark Study: A Prospective Registry and Biorepository
NCT00730002	Not specified	COMPLETED	Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TOCILIZUMAB	4	1